VASCULAR BIOGENICS LTD Sample Clauses

VASCULAR BIOGENICS LTD. (1) The undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.
Sample 1Sample 2Sample 3
AutoNDA by SimpleDocs
VASCULAR BIOGENICS LTD. CRUCELL HOLLAND B.V. For and on behalf of Crucell N.V. By: /s/ Dxxx Xxxxxx By: /s/ [Illegible] Crucell NV, represented by Or Yxxxxx, Xxxxx 00, 0000 Xxxxxx April 13, 2011 Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***]. Commercial License Agreement PER.C6® Crucell Holland – Vascular Biogenics [***] Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***]. Commercial License Agreement PER.C6® Crucell Holland – Vascular Biogenics
Sample 1
VASCULAR BIOGENICS LTD. For and on behalf of Crucell N.V. Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***]. Commercial License Agreement PER.C6® Crucell Holland – Vascular Biogenics By: /s/ [Illegible] By: /s/ Xxxx Xxxxxxxxx Name: Name: Xxxx Xxxxxxxxx Function: Function: VP Research Xxxxx Xxxxxxx Inc. By: /s/ J. Xxxxx Xxxxx, Xx. /s/ [Illegible] Name: J. Xxxxx Xxxxx, Xx. VP Strategy & Corporate Development Function: Head, Viral-based Therapeutics Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***]. Commercial License Agreement PER.C6® Crucell Holland – Vascular Biogenics ATTACHMENT 1 STATEMENT OF WORK Quotations: [***]
Sample 1
VASCULAR BIOGENICS LTD registration number 50-000000-0 a company incorporated in Israel and having its principal place of business at 6 Xxxxx Xxxxxxxxx St. Or-Yxxxxx Israel (the “Customer”) AND Biopharmax Group Ltd. registration number 50-000000-0, a private company incorporated in Israel and having its principal place of business at 4 Xxxxxxxxx Xx. Xxxxxxxxx (the “Contractor”)
Sample 1
VASCULAR BIOGENICS LTD. For and on behalf of Crucell N.V. By: /s/ Xxxxxx H.P. Xxxx By: /s/ Xxxxxxx Xxxxxxxx Name: Xxxxxx H.P. Xxxx Name: Xxxxxxx Xxxxxxxx Function: President & CEO Function: VP Business Development Leiden, October 3, 2005 Gaithersburg, September 20, 2005 BioReliance Ltd. By: /s/ Xxxxx Xxxxxx Name: Xxxxx Xxxxxx Function: Global Leader Manufacturing Glasgow, September 19, 2005 Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***]. Commercial License Agreement PER.C6® Crucell Holland – Vascular Biogenics [***]
Sample 1
VASCULAR BIOGENICS LTD. CRUCELL HOLLAND B.V. For and on behalf of Crucell N.V. By: /s/ Xxxx Xxxxxx By: /s/ [Illegible] Crucell NV, represented by Or Xxxxxx, Xxxxx 00, 0000 Xxxxxx April 13, 2011 Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***]. Exhibit 1.18 — Cell Line Designation: PER.C6® Origin of the Cell Line PER.C6® cells are [***] transformed with [***] of [***] The estimated copy number is [***] The [***] in the construct is driven by the [***] The [***] are derived from [***] Cell Line Passage History Research Master Cell Bank [***] was stored at passage number [***] on 17 January 1996. Research Working Cell Bank [***] was generated from [***] and stored at passage number [***] on 7 February 1996. The cell banks are stored in the [***] of [***] at [***] in [***] Components Used For Culture of the Cells [***] with [***] and, optionally, [***]. [***] was used for [***] Quality Control All work on the development of PER.C6® cells carried out at Crucell Holland has been carried out under controlled conditions. The data have been reviewed by QA Crucell Holland. The research Master Cell Bank and research Working Cell Bank have been tested by GLP-inspected contract testing companies. All recorded data mentioned have been reviewed by Quality Assurance, Crucell Holland BV, Leiden. All final reports have been reviewed for compliance to the specifications and pertinent relevant regulatory requirements from the US and EEC. Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***]. Commercial License Agreement PER.C6® Crucell Holland – Vascular Biogenics Safety Tests on the PER.C6® Human Adenoviral Packaging cell Line Research Master Cell Bank Test Result [***] [***] Research Working Cell Bank Test Result [***] [***] Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***]. Commercial License Agreement PER.C6® Crucell Holland – Vascular Biogenics
Sample 1

Related to VASCULAR BIOGENICS LTD

  • Baxter and Nexell shall cooperate in any action taken by a third party solely involving a nullity action, opposition, reexamination or any other action taken by such third party alleging the invalidity or unenforceability of any Licensed Intellectual Property. Both parties agree to share equally in the cost of the defense of such Licensed Intellectual Property.

  • Manufacturing Technology Transfer With respect to each Technology Transfer Product, upon AbbVie’s written request after the Inclusion Date for the Included Target to which such Technology Transfer Product is Directed, Morphic shall effect a full transfer to AbbVie or its designee (which designee may be an Affiliate or a Third Party manufacturer) of all Morphic Know-How and Joint Know-How relating to the then-current process for the Manufacture of such Technology Transfer Product (the “Manufacturing Process”) and to implement the Manufacturing Process at facilities designated by AbbVie (such transfer and implementation, as more fully described in this Section 5.3, the “Manufacturing Technology Transfer”). To assist with the Manufacturing Technology Transfer, Morphic will make its personnel reasonably available to AbbVie during normal business hours for up to [***] FTE hours with respect to each Included Target (in each case, free of charge to AbbVie) to transfer and implement the Manufacturing Process under this Section 5.3. Thereafter, if requested by AbbVie, Morphic shall continue to perform such obligations; provided, that AbbVie will reimburse Morphic for its full-time equivalent (FTE) costs (for clarity, in excess of [***] FTE hours) and any reasonable and verifiable out-of-pocket costs incurred in providing such assistance. CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED.

  • Manufacturing License Subject to the terms of this Agreement, including without limitation Section 2.2, Theravance grants to GSK an exclusive license under the Theravance Patents and Theravance Know-How to make and have made API Compound or formulated Alliance Product in the Territory.

  • Third Party Technology The assignment of any applicable license agreements with respect to Third Party Technology are set forth in the General Assignment and Assumption Agreement.

  • Motorola retains the right to subcontract, in whole or in part, any effort required to fulfill its obligations under this Agreement, provided Motorola shall remain liable for performance hereunder.

  • Medi Cal - is a federal and state funded health care program established by Title XIX of the Social Security Act, as amended, which is administered in California by the DHS.

  • Licensed Patent Rights The term “Licensed Patent Rights” shall mean rights arising out of or resulting from:

  • Commercialization Intrexon shall have the right to develop and Commercialize the Reverted Products itself or with one or more Third Parties, and shall have the right, without obligation to Fibrocell, to take any such actions in connection with such activities as Intrexon (or its designee), at its discretion, deems appropriate.

  • New Technology If New Technology becomes available from any source, including Supplier, then KP may evaluate and contract with any supplier so that KP will have access to New Technology at all times. If Supplier cannot offer New Technology at comparable or lower prices, KP may either (a) amend contract pricelist to add Supplier's New Technology at a mutually agreed-upon price; or (b) contract with other suppliers for New Technology. Regardless of whether New Technology is added to this Agreement, Supplier and KP will negotiate in good faith to equitably adjust the pricing for any current Product under this Agreement affected by the New Technology.

  • Manufacturing and Marketing Rights The Company has not granted rights to manufacture, produce, assemble, license, market, or sell its products to any other person and is not bound by any agreement that affects the Company's exclusive right to develop, manufacture, assemble, distribute, market, or sell its products.

Time is Money Join Law Insider Premium to draft better contracts faster.